Regulus Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RGLS Nasdaq 8731 https://www.regulusrx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Regulus Therapeutics Inc

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - Aug 28th, 2024 12:00 pm
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Aug 14th, 2024 10:57 am
Regulus: Q2 Earnings Snapshot - Aug 8th, 2024 9:19 pm
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - Aug 8th, 2024 8:05 pm
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Aug 6th, 2024 12:00 pm
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Jun 24th, 2024 11:00 am
Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week - Jun 14th, 2024 12:29 pm
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes - Jun 4th, 2024 12:00 pm
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - May 16th, 2024 12:00 pm
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates - May 9th, 2024 8:05 pm
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 - May 7th, 2024 10:00 am
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - May 6th, 2024 12:00 pm
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series - Apr 30th, 2024 12:00 pm
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements - Mar 23rd, 2024 9:33 am
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates - Mar 21st, 2024 8:05 pm
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More - Mar 14th, 2024 4:07 pm
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study - Mar 13th, 2024 4:09 pm
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity - Mar 12th, 2024 10:32 am
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mar 12th, 2024 10:30 am
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Jan 2nd, 2024 9:05 pm